FDA approves first generic version of Advair Diskus

31 January 2019

Netherlands-incorporated Mylan’s (Nasdaq: MYL) shares were up more than 7% at $38.82 by market close on Wednesday, following the news that the US Food and Drug Administration had finally approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder).

The branded drug is marketed by UK major GlaxoSmithKline (LSE: GSK), which has been able to fend of generic competition in the USA until now, but has been aggressively discounting in the USA. GSK’s shares dipped less than 1% in early trading today.

Advair Diskus is indicated for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD), as is Mylan’s copy version.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK